263 related articles for article (PubMed ID: 24174270)
21. ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas.
Beitler JJ; Quon H; Jones CU; Salama JK; Busse PM; Cooper JS; Koyfman SA; Ridge JA; Saba NF; Siddiqui F; Smith RV; Worden F; Yao M; Yom SS;
Head Neck; 2016 Sep; 38(9):1299-309. PubMed ID: 27330003
[TBL] [Abstract][Full Text] [Related]
22. Neck dissection for unknown cancer of the head and neck in the era of chemoradiation.
Amsbaugh MJ; Yusuf M; Gaskins J; Silverman C; Potts K; Bumpous J; Redman R; Perez C; Dunlap N
Am J Otolaryngol; 2017; 38(5):588-592. PubMed ID: 28633765
[TBL] [Abstract][Full Text] [Related]
23. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
24. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
25. Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.
Amoils M; Lee CS; Sunwoo J; Aasi SZ; Hara W; Kim J; Sirjani D; Colevas AD; Chang AL; Divi V
Head Neck; 2017 May; 39(5):881-885. PubMed ID: 28252823
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of posttreatment neutrophil-lymphocyte ratio in head and neck squamous cell carcinoma treated by chemoradiotherapy.
Kim DY; Kim IS; Park SG; Kim H; Choi YJ; Seol YM
Auris Nasus Larynx; 2017 Apr; 44(2):199-204. PubMed ID: 27269133
[TBL] [Abstract][Full Text] [Related]
27. Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
David JM; Ho AS; Luu M; Yoshida EJ; Kim S; Mita AC; Scher KS; Shiao SL; Tighiouart M; Zumsteg ZS
Cancer; 2017 Oct; 123(20):3933-3942. PubMed ID: 28640546
[TBL] [Abstract][Full Text] [Related]
28. Determinants of complications and outcome in high-risk squamous cell head-and-neck cancer treated with perioperative high-dose rate brachytherapy (PHDRB).
Martínez-Monge R; Pagola Divassón M; Cambeiro M; Gaztañaga M; Moreno M; Arbea L; Montesdeoca N; Alcalde J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e245-54. PubMed ID: 21620582
[TBL] [Abstract][Full Text] [Related]
29. Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer.
Campian JL; Ye X; Sarai G; Herman J; Grossman SA
Cancer Invest; 2018; 36(6):356-361. PubMed ID: 30095290
[TBL] [Abstract][Full Text] [Related]
30. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
32. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
33. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy.
Manyam BV; Gastman B; Zhang AY; Reddy CA; Burkey BB; Scharpf J; Alam DS; Fritz MA; Vidimos AT; Koyfman SA
J Am Acad Dermatol; 2015 Aug; 73(2):221-7. PubMed ID: 26028524
[TBL] [Abstract][Full Text] [Related]
34. HPV Infection and Anemia Status Stratify the Survival of Early T2 Laryngeal Squamous Cell Carcinoma.
Wang H; Zhang Z; Sun R; Lin H; Gong L; Fang M; Hu WH
J Voice; 2015 May; 29(3):356-62. PubMed ID: 25484261
[TBL] [Abstract][Full Text] [Related]
35. Using routine data to estimate survival and recurrence in head and neck cancer: our preliminary experience in twenty patients.
Liu ZW; Fitzke H; Williams M
Clin Otolaryngol; 2013 Aug; 38(4):334-9. PubMed ID: 23621396
[No Abstract] [Full Text] [Related]
36. [Neutrophil to lymphocyte ratio in peripheral blood: a novel independent prognostic factor in patients with head and neck squamous cell carcinoma].
Wu F; Wu LL; Zhu LX
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):29-32. PubMed ID: 28104030
[No Abstract] [Full Text] [Related]
37. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma.
Cho O; Chun M; Oh YT; Noh OK; Chang SJ; Ryu HS; Lee EJ
Tumour Biol; 2017 Oct; 39(10):1010428317733144. PubMed ID: 29022484
[TBL] [Abstract][Full Text] [Related]
39. Preoperative simultaneous fractionated cisplatin and radiation therapy in the treatment of advanced operable stage III and IV squamous cell carcinoma of the head and neck.
Davis MA; Tyrrell J; Slotman GJ; Sudhindra R; Sachdeva K; Fanelle J; Smith G; Wurzer JV; Cassir J; Nazha NT;
Am J Surg; 2015 Mar; 209(3):575-9. PubMed ID: 25557972
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy.
Platek ME; Reid ME; Wilding GE; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Warren GW; Sullivan M; Thorstad WL; Khan MK; Loree TR; Singh AK
Head Neck; 2011 Nov; 33(11):1561-8. PubMed ID: 21990220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
